We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of PIFA PLUSS PF4 Rapid Assay

6 Dec 2011 07:00

RNS Number : 3983T
Akers Biosciences, Inc.
06 December 2011
 



Embargoed: 0700hrs, 6 December 2011

 

Akers Biosciences, Inc.

("ABI" or the "Company")

 

Launch of revolutionary PIFA PLUSS PF4 Rapid Assay

whole blood technology

 

Akers Biosciences, Inc. (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce that its patented blood cell separator technology (the "Technology") will be integrated into the Company's PIFA Rapid Assay platform and launched into market in January 2012.

 

The Technology enables the immediate separation of serum (the liquid component of blood) from a patient's finger stick or venous whole blood sample and then introduces the extracted specimen into a rapid assay device to provide a real-time result. In addition, whole blood treated with certain anticoagulants, commonly used in some coagulation laboratories, will now be compatible with the Company's PIFA Rapid Assay platform.

 

The Technology, which fulfills all of the requirements of the FDA for marketability, is designed to be adaptable and can also be applied to other diagnostic testing methodologies.  

 

This enhancement drastically improves assay turn-around-time which is critical not only to point-of-care ("POC") screening, but to all in vitro diagnostic testing overseen by the laboratory. In the Company's interim statement of 7 September 2011, the product was referred to as "PIFA POC"; it will now be branded under the trade name PIFA PLUSS to represent the addition of our Serum Separation technology into the PIFA platform.

 

The initial introduction of this product line extension will expand the Company's franchise in the Heparin-Induced Thrombocytopenia ("HIT") rapid testing market. The PIFA PLUSS PF4 Rapid Assay will be uniquely positioned as the only whole blood, disposable screening device for the rapid detection of antibodies which are a major determinant in the pathogenesis of HIT, a life-and limb-threatening complication of treatment with the blood-thinner Heparin.

 

The Company plans to apply the Technology to many of its other diagnostic products, including its infectious disease suite of rapid assays, which includes diagnosis of Chlamydia and Malaria. In the USA, the PIFA PLUSS PF4 Rapid Assay will be sold to end-users exclusively by ABI's direct sales force; the Company is actively seeking partners for non-USA distribution.

Thomas A. Nicolette, President & CEO, commented:

 

"With an industry shift towards expedited test results in the clinical laboratory and at the point-of-care, the forthcoming launch of our revolutionary blood cell separator technology within our PIFA platform represents a breakthrough in diagnostic testing.

 

PIFA PLUSS narrows the entire test procedure, inclusive of sample preparation, to a timeline measured in minutes, versus traditional more labour -intensive and slower methods which can involve samples being sent away to external laboratories. The product further demonstrates our continued dedication to technology enhancement and to delivering clinically-relevant information for laboratorians, and the physicians whom they support, in a timely and cost-efficient manner.

 

In addition to the anticipated value this Technology will bring to ABI's portfolio, the adaptability of the Technology may lead to partnerships with other diagnostic firms for use on their own platforms."

 

Enquiries:

 

Thomas A. Nicolette, President and CEO

Dr. Raymond F. Akers, Jr., Executive Chairman

Tel. +1 856 848 8698

 

Noelle Greenaway

Daniel Stewart & Company plc (Nominated Adviser and Broker)

Tel. +44(0)20 7776 6550

 

Ben Simons

M: Communications

Tel. +44(0)20 7920 2340

 

About Akers Biosciences, Inc.

 

Akers Biosciences develops, manufactures, and supplies rapid, point-of-care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical product distributorsto maximise product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFSSEFIFFSEFE
Date   Source Headline
14th Jul 20177:00 amRNSNotice of AGM & Directorate Changes
3rd Jul 20172:53 pmRNSForm S-3 Registration Statement
9th Jun 20174:51 pmRNSIssue of Equity
16th May 20177:00 amRNS1st Quarter Results
12th May 20172:30 pmRNSNotice of Q1 Results
5th May 201710:53 amRNSIssue of Equity
24th Apr 20175:12 pmRNSIssue of Equity
11th Apr 20179:13 amRNSHolding(s) in Company
11th Apr 20177:00 amRNSFinal Results
10th Apr 20173:00 pmRNSNotice of Results
10th Apr 201712:00 pmRNSIssue of Equity
10th Apr 20177:00 amRNSHeparin PF4 Rapid Test in Puerto Rico
6th Apr 20175:39 pmRNSIssue of Equity
4th Apr 20174:18 pmRNSIssue of Equity
31st Mar 20177:00 amRNSIssue of Equity
30th Mar 20171:30 pmRNSDetailed Year-end Trading Update
29th Mar 20177:00 amRNSNotice of Results
28th Mar 201712:00 pmRNSInitial Order for Rapid Cholesterol Self-test
16th Feb 20177:00 amRNSUS Patent for Akers Wellness Tests Cartridge
1st Feb 20177:00 amRNSTrading Update
13th Jan 20177:00 amRNSIssue of Equity
10th Jan 20177:00 amRNSIssue of Equity
9th Jan 20177:00 amRNSSupplement to Form S-3 Registration Statement
19th Dec 20165:00 pmRNSResult of AGM
19th Dec 20167:00 amRNSAgreement with GNYHA for PIFA Heparin PF4 Test
1st Dec 201612:00 pmRNSUS Distribution Agreement: Cholesterol Self-test
28th Nov 20167:06 amRNSClinical Trial for BreathScan DKA Completed
17th Nov 20167:00 amRNSSupplement to Form S-3 Registration Statement
14th Nov 201612:00 pmRNSNotice of AGM
14th Nov 20167:00 amRNS3rd Quarter Results
10th Nov 20167:00 amRNSEuropean Patent Granted
9th Nov 20164:29 pmRNSNotice of Q3 Results
25th Oct 20167:00 amRNSFiling of Form S-3 Registration Statement
19th Aug 20167:00 amRNSSettlement of Dispute with ChubeWorkx
18th Aug 20167:00 amRNSResults of OxiChek Test Study
11th Aug 20167:00 amRNSHalf Yearly Results
9th Aug 20164:00 pmRNSNotice of H1 2016 Earnings
30th Jun 20167:00 amRNSClinical Trial for Rapid Chlamydia Test Completed
27th Jun 20167:00 amRNSDistribution Agreement for BreathScan OxiChekT
14th Jun 201612:00 pmRNSIssue of Equity & PDMR Shareholding
26th May 20165:10 pmRNSPDMR Shareholding
12th May 20167:00 amRNSFinancial Results for Q1 2016
10th May 201612:00 pmRNSNotice of Q1 Results
25th Apr 201612:00 pmRNSBoard Rearrangement
30th Mar 20167:00 amRNSFinal Results
23rd Mar 20167:00 amRNSUS Patent - Heparin/PF4 Antibody Detection
16th Mar 20167:00 amRNSNotice of Results
2nd Mar 20167:00 amRNS$2.5M Product Order
29th Feb 20167:00 amRNSSenior Commercial Team Appointments
6th Jan 20167:00 amRNSDirectors Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.